GCNT3, aa273-284 (Gucosaminyl (N-acetyl) transferase 3, mucin type, C2/4GnT, C2GnT-M, C2GnT2, GnT-M, beta1, 6-N-acetyl glucosaminyl transferase) (Control Peptide)

General information
 

Name:
GCNT3, aa273-284 (Gucosaminyl (N-acetyl) transferase 3, mucin type, C2/4GnT, C2GnT-M, C2GnT2, GnT-M, beta1, 6-N-acetyl glucosaminyl transferase) (Control Peptide)
Size:
0,1 mg
Catalog no:
MBS633917
Price:
492 EUR
 

Additional extra details
 

  • Other size

    please contact us to order other different size

    Tissue

    control

    Description

    N terminal acetylation or CH3CO as epigenetic regulation of GCNT3, aa273-284 (Gucosaminyl (N- ) transferase 3, mucin C2/4GnT, C2GnT-M, C2GnT2, GnT-M, beta1, 6-N- glucosaminyl transferase) (Control Peptide) by NATs.Isotype or positive controls by peptides, antibodies and deactivated samples.Peptides short amino acid chains or epitopes or blocking antagonists. The shortest peptides are dipeptides, consisting of 2 amino acids joined by a single peptide bond, followed by tripeptides, tetra peptides, ... till polypeptides that are long, continuous, and unbranched synthetic peptide chains. These biological oligomers and polymers can be Solid-phase peptide synthesis (SPPS), or in continue produced for custom peptide synthesis projects. The High-efficiency solid phase peptide synthesis (HE-SPPS) is give very low production costs.